The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.

Yaning YangHaiyan XuGuangjian YangLu YangJunling LiYan Wang

Published in: Asia-Pacific journal of clinical oncology (2019)

Trend of NLR, dNLR, PLR and WBC could be used to identify patients progress status in ALK-positive NSCLC patients receiving crizotinib. Combination of all biomarkers is no superior to single biomarker.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
epidermal growth factor receptor
small cell lung cancer
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported